1 O'Brien S, et al. Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small lympocytic leukemia. ASH 2016. Abstract #233. | ||
2 IMS Database [Data on File] | ||
3 American Cancer Society. What are the key statistics for chronic lymphocytic leukemia? Available from: http://www.cancer.org/cancer/leukemia-chroniclymphocyticcll/detailedguide/leukemia-chronic-lymphocytic-key-statistics. Accessed November 2016. | ||
4 American Cancer Society. Leukemia – Chronic Lymphocytic. Available from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003111-pdf.pdf. Accessed November 2016 | ||
5 Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42. | ||
6 Barr P, et al. Updated efficacy and safety from the phase 3 RESONATE-2 Study: Ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia. ASH 2016. Abstract #234. | ||
7 Burger JA, Tedeschi PM, Barr TR, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015;373:2425--37. | ||
8 Coutre S., et al. Integrated and long-term safety analysis of ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. ASH 2016. Abstract #4383. | ||
9 Kipps T, et al. Deletion (del11q) is not a prognostic factor for adverse outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with ibrutinib: Pooled data from 3 randomized phase 3 studies. ASH 2016. Abstract #2042. | ||
10 IMBRUVICA US Prescribing Information, June 2016. | ||
11 Genetics Home Reference. Isolated growth hormone deficiency. Available from: http://ghr.nlm.nih.gov/condition/isolated-growth-hormone-deficiency. Accessed Novemberr 2016. |